Abstracts

Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes

Ophthalmic Res. 2015;55(2):84-90. doi: 10.1159/000440886. Epub 2015 Dec 5.
Chang AA 1 , Broadhead GK, Hong T, Joachim N, Syed A, Schlub TE, Toth L, Peto T, Zhu M.

ABSTRACT

Purpose
To prospectively assess the safety and efficacy of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration (nAMD).

Methods
This prospective, non-randomized clinical trial included 49 patients with treatment-resistant nAMD who received 2 mg intravitreal aflibercept as 3 monthly loading doses, followed by injections every 2 months over 12 months. Inclusion criteria included active nAMD on fluorescein angiography at baseline and persistent intra- or subretinal fluid on optical coherence tomography (OCT) for; 6 months prior to baseline with a minimum of 4 injections of bevacizumab and/or ranibizumab. Patients were assessed monthly for best-corrected visual acuity (BCVA), central retinal thickness (CRT) measured with OCT and occurrence of adverse events. Retinal pigment epithelium atrophy (RPEA) was assessed at baseline and at 12 months.

Results
Mean BCVA improved by 4.7 letters (95% CI: 2.1-7.3, p < 0.001) and CRT decreased by 97.2┬Ám (95% CI: 54.4-140.1, p < 0.001) at 12 months compared to baseline. Median RPEA area increased by 0.48 mm2 (range = -0.1 to 19.9, p < 0.001). There was 1 arterial thromboembolic event and 2 cases of submacular haemorrhage.

Conclusion
In this cohort of treatment-resistant nAMD patients, intravitreal aflibercept was effective in improving vision and reducing exudation. Early visual and anatomic outcomes may predict longer-term response to treatment, but further assessment is required.

http://www.ncbi.nlm.nih.gov/pubmed/26637166

OTHER Abstracts
  • Abstracts

    Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration.

    Acta Ophthalmol. 2014 Dec;92(8):713-23. doi: 10.1111/aos.12463. Epub 2014 Jun 12. Broadhead GK 1 , Hong T, Chang AA.

    Read more
  • Abstracts

    Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes.

    Graefes Arch Clin Exp Ophthalmol. 2015 Aug;253(8):1217-25. doi: 10.1007/s00417-014-2799-8. Epub 2014 Sep 10. Zhu M 1 , Chew

    Read more
  • Abstracts

    Dietary modification and supplementation for the treatment of age-related macular degeneration.

    Nutr Rev. 2015 Jul;73(7):448-62. doi: 10.1093/nutrit/nuv005. Epub 2015 Apr 28. Broadhead GK 1 , Grigg JR 2 ,

    Read more
More Abstracts